C Warren Olanow

List of Publications by Year
in descending order

105 papers	23,446 citations	25034 57 h-index	31849 101 g-index
150 all docs	150 docs citations	150 times ranked	19069 citing authors

#	Article	IF	Citations
1	Parkinson's Disease Modification Through Abl Kinase Inhibition: An Opportunity. Movement Disorders, 2022, 37, 6-15.	3.9	21
2	Continuous Subcutaneous Levodopa Delivery for Parkinsonâ€™s Disease: A Randomized Study. Journal of Parkinson's Disease, 2021, 11, 177-186.	2.8	33
3	A New Approach to the Development of Diseaseâ€Modifying Therapies for PD ; Fighting Another Pandemic. Movement Disorders, 2021, 36, 59-63.	3.9	13
4	<scp>Onâ€Demand</scp> Therapy for <scp>OFF</scp> Episodes in Parkinson's Disease. Movement Disorders, 2021, 36, 2244-2253.	3.9	16
5	Subcutaneous Levodopa Infusion for Parkinson's Disease: 1<scp>â€Year</scp> Data from the <scp>Openâ€Label BeyoND</scp> Study. Movement Disorders, 2021, 36, 2687-2692.	3.9	20
6	Dose optimization of apomorphine sublingual film for treating â€œOFFâ€episodes in Parkinson's disease. Parkinsonism and Related Disorders, 2021, 93, 27-30.	2.2	8
7	Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study. Lancet Neurology, The, 2020, 19, 135-144.	10.2	80
8	Effects of Pridopidine on Functional Capacity in Early-Stage Participants from the PRIDE-HD Study. Journal of Huntington's Disease, 2020, 9, 371-380.	1.9	17
9	Continuous Dopaminergic Stimulation as a Treatment for Parkinson's Disease: Current Status and Future Opportunities. Movement Disorders, 2020, 35, 1731-1744.	3.9	47
10	Long-term post-mortem studies following neurturin gene therapy in patients with advanced Parkinsonâ€™s disease. Brain, 2020, 143, 960-975.	7.6	56
11	<scp>Onceâ€Weekly</scp> Subcutaneous Delivery of <scp>Polymerâ€Linked</scp> Rotigotine (<scp>SER</scp>â€214) Provides Continuous Plasma Levels in Parkinson's Disease Patients. Movement Disorders, 2020, 35, 1055-1061.	3.9	24
12	Temporal evolution of microglia and Î±-synuclein accumulation following foetal grafting in Parkinsonâ€™s disease. Brain, 2019, 142, 1690-1700.	7.6	75
13	Movement Disorders Journal: Yesterday, Today, Tomorrow, and Always. Movement Disorders, 2019, 34, 1814-1816.	3.9	1
14	Continuous versus intermittent oral administration of levodopa in Parkinson's disease patients with motor fluctuations: A pharmacokinetics, safety, and efficacy study. Movement Disorders, 2019, 34, 425-429.	3.9	11
15	Levodopa: A new look at an old friend. Movement Disorders, 2018, 33, 859-866.	3.9	89
16	Adverse event reporting in clinical trials in Parkinson's Disease: Time for change. Movement Disorders, 2018, 33, 1685-1687.	3.9	1
17	Movement disorder society criteria for clinically established early Parkinson's disease. Movement Disorders, 2018, 33, 1643-1646.	3.9	114
18	Targeting Î±-Synuclein as a therapy for Parkinson's disease: The battle begins. Movement Disorders, 2017, 32, 203-207.	3.9	26

#	Article	IF	Citations
19	Robust graft survival and normalized dopaminergic innervation do not obligate recovery in a <scp>P</scp>arkinson disease patient. Annals of Neurology, 2017, 81, 46-57.	5.3	72
20	Translating scientific advances into disease-modifying therapies for Parkinson's Disease. Experimental Neurology, 2017, 298, 135-136.	4.1	1
21	Clinical development of a poly(2-oxazoline) (POZ) polymer therapeutic for the treatment of Parkinsonâ€™s disease â€“ Proof of concept of POZ as a versatile polymer platform for drug development in multiple therapeutic indications. European Polymer Journal, 2017, 88, 524-552.	5.4	124
22	Eldad Melamed 1942-2015: Ave atque-A memorial. Movement Disorders, 2016, 31, 39-40.	3.9	0
23	Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease. Movement Disorders, 2016, 31, 1366-1372.	3.9	67
24	Longâ€term effects of rasagiline and the natural history of treated Parkinson's disease. Movement Disorders, 2016, 31, 1489-1496.	3.9	45
25	Fetal grafts for Parkinsonâ€™s disease: Decades in the making. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 6332-6334.	7.1	8
26	Trophic factors for Parkinson's disease: To live or let die. Movement Disorders, 2015, 30, 1715-1724.	3.9	55
27	Gene delivery of neurturin to putamen and substantia nigra in <scp>P</scp>arkinson disease: A doubleâ€blind, randomized, controlled trial. Annals of Neurology, 2015, 78, 248-257.	5.3	224
28	Advances in clinical trials for movement disorders. Movement Disorders, 2015, 30, 1580-1587.	3.9	8
29	Targeting Î±-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations. Lancet Neurology, The, 2015, 14, 855-866.	10.2	393
30	Levodopa: Effect on cell death and the natural history of Parkinson's disease. Movement Disorders, 2015, 30, 37-44.	3.9	83
31	Profile of Mahlon DeLong and Alim Benabid, 2014 Lasker-DeBakey Medical Research Awardees. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 17693-17695.	7.1	2
32	Gene therapy for Parkinson diseaseâ€”a hope, or a dream?. Nature Reviews Neurology, 2014, 10, 186-187.	10.1	12
33	Do prions cause Parkinson disease?: The evidence accumulates. Annals of Neurology, 2014, 75, 331-333.	5.3	34
34	Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurology, The, 2014, 13, 141-149.	10.2	547
35	Initiating levodopa therapy for Parkinson's disease. Movement Disorders, 2014, 29, 430-430.	3.9	5
36	Peripheral alphaâ€synuclein and Parkinson's disease. Movement Disorders, 2014, 29, 963-966.	3.9	32

#	Article	IF	Citations
37	Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Lancet Neurology, The, 2014, 13, 767-776.	10.2	120
38	Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives. Lancet, The, 2014, 384, 545-555.	13.7	336
39	Factors predictive of the development of Levodopaâ€induced dyskinesia and wearingâ€off in Parkinson's disease. Movement Disorders, 2013, 28, 1064-1071.	3.9	374
40	Disease duration and the integrity of the nigrostriatal system in Parkinsonâ€™s disease. Brain, 2013, 136, 2419-2431.	7.6	965
41	Therapeutic prospects for Parkinson disease. Annals of Neurology, 2013, 74, 337-347.	5.3	122
42	Parkinson's Disease and Alpha Synuclein: Is Parkinson's Disease a Prionâ€Like Disorder?. Movement Disorders, 2013, 28, 31-40.	3.9	320
43	The Vatican Meeting on Neuroprotection for Parkinson's Disease. Movement Disorders, 2013, 28, 1-2.	3.9	26
44	The state of the journalâ€”2013. Movement Disorders, 2013, 28, 259-260.	3.9	0
45	The significance of defining preclinical or prodromal Parkinson's disease. Movement Disorders, 2012, 27, 666-669.	3.9	69
46	Milestones in movement disorders clinical trials: Advances and landmark studies. Movement Disorders, 2011, 26, 1003-1014.	3.9	16
47	The Movement Disorders journal-Then and now. Movement Disorders, 2011, 26, 935-936.	3.9	0
48	Parkinson's disease, proteins, and prions: Milestones. Movement Disorders, 2011, 26, 1056-1071.	3.9	36
49	New Sections for Movement Disorders. Movement Disorders, 2011, 26, 2179-2179.	3.9	0
50	Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurology, The, 2010, 9, 1164-1172.	10.2	589
51	Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDEâ€PD study. Annals of Neurology, 2010, 68, 18-27.	5.3	330
52	The baton is passed. Movement Disorders, 2010, 25, 1-1.	3.9	5
53	Defining diseaseâ€modifying therapies for PDâ€”A road map for moving forward. Movement Disorders, 2010, 25, 1774-1779.	3.9	31
54	The delayed-start study in Parkinson disease. Neurology, 2010, 74, 1149-1150.	1.1	21

#	Article	IF	Citations
55	The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology, 2009, 72, S1-136.	1.1	685
56	Is Parkinson's disease a prion disorder?. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 12571-12572.	7.1	242
57	Can we achieve neuroprotection with currently available anti-parkinsonian interventions?. Neurology, 2009, 72, S59-64.	1.1	57
58	Reply to Montgomery. Annals of Neurology, 2009, 65, 618-619.	5.3	5
59	Dopaminergic transplantation for parkinson's disease: Current status and future prospects. Annals of Neurology, 2009, 66, 591-596.	5.3	80
60	Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: A double blind videoâ€based analysis. Movement Disorders, 2009, 24, 336-343.	3.9	84
61	A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease. New England Journal of Medicine, 2009, 361, 1268-1278.	27.0	830
62	Levodopa therapy for Parkinson's disease: Challenges and future prospects. Movement Disorders, 2008, 23, S495-S496.	3.9	14
63	Levodopa/dopamine replacement strategies in Parkinson's disease-Future directions. Movement Disorders, 2008, 23, S613-S622.	3.9	52
64	A randomized, doubleâ€blind, placeboâ€controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics. Movement Disorders, 2008, 23, 2194-2201.	3.9	162
65	Movement Disorder Societyâ€sponsored revision of the Unified Parkinson's Disease Rating Scale (MDSâ€UPDRS): Scale presentation and clinimetric testing results. Movement Disorders, 2008, 23, 2129-2170.	3.9	4,796
66	Lewy bodyâ€“like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nature Medicine, 2008, 14, 504-506.	30.7	1,472
67	The Etiopathogenesis of Parkinson's Disease: Basic Mechanisms of Neurodegeneration. , 2008, , 1-23.		0
68	Why have we failed to achieve neuroprotection in Parkinson's disease?. Annals of Neurology, 2008, 64, S101-S110.	5.3	125
69	Tolcapone. Clinical Neuropharmacology, 2007, 30, 287-294.	0.7	83
70	The pathogenesis of cell death in Parkinson's disease â€“ 2007. Movement Disorders, 2007, 22, S335-S342.	3.9	191
71	Drug Insight: continuous dopaminergic stimulation in the treatment of Parkinson's disease. Nature Clinical Practice Neurology, 2006, 2, 382-392.	2.5	117
72	Movement disorders: a step in the right direction. Lancet Neurology, The, 2006, 5, 3-5.	10.2	5

#	Article	IF	Citations
73	Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurology, The, 2006, 5, 677-687.	10.2	461
74	TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurology, The, 2006, 5, 1013-1020.	10.2	167
75	Ubiquitinâ€“proteasome system and Parkinson's disease. Movement Disorders, 2006, 21, 1806-1823.	3.9	175
76	Rationale for considering that propargylamines might be neuroprotective in Parkinsonâ€™s disease. Neurology, 2006, 66, S69-79.	1.1	67
77	A Model-Based Approach for Assessing Parkinsonian Gait and Effects of Levodopa and Deep Brain Stimulation. Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 2006, , .	0.5	0
78	Reply: Levodopa in the treatment of Parkinson's disease: Current controversies. Movement Disorders, 2005, 20, 643-644.	3.9	7
79	Neuroprotective therapy in Parkinson's disease and motor complications: A search for a pathogenesis-targeted, disease-modifying strategy. Movement Disorders, 2005, 20, S3-S10.	3.9	55
80	Intermittent vs Continuous Levodopa Administration in Patients With Advanced Parkinson Disease. Archives of Neurology, 2005, 62, 905-10.	4.5	206
81	Levodopa and the Progression of Parkinson's Disease. New England Journal of Medicine, 2004, 351, 2498-2508.	27.0	1,649
82	Lewy-body formation is an aggresome-related process: a hypothesis. Lancet Neurology, The, 2004, 3, 496-503.	10.2	278
83	The Scientific Basis for the Current Treatment of Parkinson's Disease. Annual Review of Medicine, 2004, 55, 41-60.	12.2	165
84	Levodopa in the treatment of Parkinson's disease: Current controversies. Movement Disorders, 2004, 19, 997-1005.	3.9	331
85	Multicenter, Open-Label, Trial of Sarizotan in Parkinson Disease Patients With Levodopa-Induced Dyskinesias (the SPLENDID Study). Clinical Neuropharmacology, 2004, 27, 58-62.	0.7	161
86	COMT inhibitors in Parkinsonâ€™s disease. Neurology, 2004, 62, S72-81.	1.1	70
87	Dietary vitamin E and Parkinson's disease: something to chew on. Lancet Neurology, The, 2003, 2, 74.	10.2	15
88	A doubleâ€blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Annals of Neurology, 2003, 54, 403-414.	5.3	1,450
89	Present and future directions in the management of motor complications in patients with advanced PD. Neurology, 2003, 61, S24-33.	1.1	17
90	Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease. Brain, 2002, 125, 2058-2066.	7.6	145

#	Article	IF	Citations
91	Glial Cells Mediate Toxicity in Glutathione-Depleted Mesencephalic Cultures. Journal of Neurochemistry, 2002, 73, 112-119.	3.9	46
92	The role of dopamine agonists in the treatment of early Parkinsonâ€™s disease. Neurology, 2002, 58, S33-41.	1.1	32
93	Failure of the ubiquitinâ€“proteasome system in Parkinson's disease. Nature Reviews Neuroscience, 2001, 2, 589-594.	10.2	490
94	Waking up to sleep episodes in Parkinson's Disease. Movement Disorders, 2000, 15, 212-215.	3.9	163
95	Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's disease. Movement Disorders, 2000, 15, 485-489.	3.9	60
96	Pathophysiology of the basal ganglia in Parkinson's disease. Trends in Neurosciences, 2000, 23, S8-S19.	8.6	702
97	Parkinsonism associated with Sjï¿½gren's syndrome: Three cases and a review of the literature. Movement Disorders, 1999, 14, 262-268.	3.9	51
98	Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease. Movement Disorders, 1998, 13, 383-393.	3.9	271
99	Understanding cell death in parkinson's disease. Annals of Neurology, 1998, 44, S72-84.	5.3	605
100	Subthalamic nucleusâ€mediated excitotoxicity in parkinson's disease: A target for neuroprotection. Annals of Neurology, 1998, 44, S175-88.	5.3	344
101	Dopamine agonists and neuroprotection in parkinson's disease. Annals of Neurology, 1998, 44, S167-74.	5.3	108
102	The causes of parkinson's disease are being unraveled and rational neuroprotective therapy is close to reality. Annals of Neurology, 1998, 44, S189-96.	5.3	65
103	Fetal Grafting for Parkinson's Disease: Expression of Immune Markers in Two Patients with Functional Fetal Nigral Implants. Cell Transplantation, 1997, 6, 213-219.	2.5	107
104	<scp>l</scp>â€Deprenyl Protects Mesencephalic Dopamine Neurons from Glutamate Receptorâ€Mediated Toxicity In Vitro. Journal of Neurochemistry, 1997, 68, 33-39.	3.9	89
105	<scp>l</scp>â€(â^')â€Desmethylselegiline, a Metabolite of Selegiline [<scp>l</scp>â€(â^')â€Deprenyl], Protects Mesencephalic Dopamine Neurons from Excitotoxicity In Vitro. Journal of Neurochemistry, 1997, 68, 434-436.	3.9	61